For Patients with End-Stage Renal Disease, Mortality After TAVR Is High

In a registry-based study, 1-year mortality with transcatheter aortic valve replacement was 37%, almost twofold higher than in patients without ESRD.

In patients receiving surgical aortic valve replacement (AVR), the presence of end-stage renal disease (ESRD) is associated with higher perioperative and later mortality. To see whether this would be also true for transcatheter AVR (TAVR), researchers analyzed data from the Society of Thoracic Surgeons (STS)/American College of Cardiology TVT Registry on all 72,631 commercial U.S. TAVR procedures performed between 2011 and 2016.

A total of 3053 patients (4.2%) had ESRD and were on dialysis. These patients were younger than those without ESRD (median age, 76 vs. 83) and more likely to be black (14.5% vs. 3.3%) and had more comorbid conditions and higher risks for surgery (STS's Predicted Risk of Mortality scores, 13.5% vs. 6.2%). Although in-…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI

Leadership Positions in Professional SocietiesHeart Valve Collaboratory (Scientific Committee Member, Chair of the Publications Committee)